← back to search

Dietmar Pfeifer

University of Freiburg · DE
Area of research
Immunology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, Immune Cell Function and Interaction, Immunodeficiency and Autoimmune Disorders, and Chronic Lymphocytic Leukemia Research.
h-index
55
citations
14,900
works
299
NIH funding
primary concept
Biology
email

Recent publications

Supplementary Figures from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2026cited by 0position: contributordoi
Data from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2026cited by 0position: contributordoi
Supplementary Tables from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2026cited by 0position: contributordoi
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
Cancer Cell 2025cited by 39position: middledoi
Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling
Nature Communications 2025cited by 5position: middledoi
Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
Blood Cancer Discovery 2025cited by 4position: middledoi
Gut microbiota-derived TMAVA is a modulator of acute CNS-GVHD.
2025cited by 3position: contributordoi
Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.
2025cited by 3position: contributordoi
Sensitization of Non‐<scp>M3</scp> Acute Myeloid Leukemia Blasts to All‐<i>Trans</i> Retinoic Acid by the <scp>LSD1</scp> Inhibitor Tranylcypromine: <scp>TRANSATRA</scp> Phase I Study
European Journal Of Haematology 2025cited by 1position: middledoi
Figure 6 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 7 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 5 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 1 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Supplementary Figures from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 2 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Supplementary Tables from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 4 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Figure 3 from Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
2025cited by 0position: contributordoi
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
Nature Cancer 2024cited by 37position: middledoi
Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease
Science Translational Medicine 2024cited by 28position: middledoi
Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease.
2024cited by 27position: contributordoi
Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
Science Translational Medicine 2024cited by 24position: middledoi
Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation.
2024cited by 22position: contributordoi
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
Cancer Research 2024cited by 21position: middledoi
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.
2024cited by 17position: contributordoi
ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease
Nature Communications 2024cited by 13position: middledoi
Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues-Brief Report.
2024cited by 7position: contributordoi
Impact of <i>TP53</i> Mutation Status in Elderly <scp>AML</scp> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine
European Journal Of Haematology 2024cited by 6position: middledoi
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
Clinical Epigenetics 2024cited by 4position: middledoi
Pyjacker identifies enhancer hijacking events in acute myeloid leukemia including <i>MNX1</i> activation via deletion 7q
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Justus Duyster · University of Freiburg19 papers (2017–2025)Michael Lübbert · University of Freiburg15 papers (2012–2025)Tilman Brummer · University of Freiburg14 papers (2014–2024)Bruce R. Blazar · First Affiliated Hospital of Soochow University13 papers (2016–2024) · 12 papers (2023–2024)Robert Zeiser · I.C. Medical (United States)11 papers (2014–2025)Sanaz Taromi · University of Freiburg11 papers (2023–2024)Mitchell P. Levesque · Swiss Continence Foundation11 papers (2023–2024)Robert Zeiser · I.C. Medical (United States)11 papers (2023–2024)Susana Minguet · University Hospital and Clinics11 papers (2023–2024)Burkhard Becher · University of Zurich11 papers (2023–2024)Hans D. Menssen · Novartis (Switzerland)11 papers (2023–2024)Melanie Boerries · National Center for Tumor Diseases11 papers (2023–2024)Geoffroy Andrieux · University Medical Center Freiburg11 papers (2023–2024)Sophie Giesler · University of Freiburg11 papers (2023–2024)Tobias Wertheimer · University of Freiburg11 papers (2023–2024)Sandra Duquesne · University of Freiburg11 papers (2023–2024)Sara Costa-Pereira · University of Zurich11 papers (2023–2024)Lukas Rindlisbacher · University of Zurich11 papers (2023–2024) · 11 papers (2023–2024)